Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
OSTEOPOROSIS INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-11
DOI
10.1007/s00198-020-05590-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial
- (2019) Silvina Gallo et al. DIABETES OBESITY & METABOLISM
- Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies
- (2019) A. Salari-Moghaddam et al. OSTEOPOROSIS INTERNATIONAL
- Risk of bone fracture associated with sodium–glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials
- (2019) L. Cheng et al. DIABETES & METABOLISM
- Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis
- (2019) Xiaoyu Li et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin use and fracture risk in patients with type 2 diabetes: A meta‑analysis of 138,690�patients
- (2019) Yuxian Zhang et al. Experimental and Therapeutic Medicine
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
- (2019) Zien Zhou et al. DIABETOLOGIA
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta‐analysis
- (2019) Zhen Zhang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Type 2 Diabetes in Relation to Hip Bone Density, Area, and Bone Turnover in Swedish Men and Women: A Cross-Sectional Study
- (2018) Adam Mitchell et al. CALCIFIED TISSUE INTERNATIONAL
- Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study
- (2018) Niklas Schmedt et al. DIABETES OBESITY & METABOLISM
- Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
- (2018) P. C. Lee et al. Obesity Reviews
- Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
- (2018) Y. S. Zhang et al. OSTEOPOROSIS INTERNATIONAL
- Metformin; an old antidiabetic drug with new potentials in bone disorders
- (2018) Saman Bahrambeigi et al. BIOMEDICINE & PHARMACOTHERAPY
- Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials
- (2018) Md Azharuddin et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of ankle fracture surgery on glycemic control in patients with diabetes
- (2016) Seung Yeol Lee et al. BMC MUSCULOSKELETAL DISORDERS
- Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
- (2016) H. L. Tang et al. DIABETES OBESITY & METABOLISM
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mechanisms of diabetes mellitus-induced bone fragility
- (2016) Nicola Napoli et al. Nature Reviews Endocrinology
- Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial
- (2016) Wenying Yang et al. Journal of Diabetes
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
- (2015) Hsin-Hung Chen et al. PLoS One
- Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial
- (2015) Chieh-Hsiang Lu et al. Journal of Diabetes Investigation
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies
- (2012) Lili Ma et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Is chronic hyponatremia a novel risk factor for hip fracture in the elderly?
- (2012) J. Carlos Ayus et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search